Group 1 - The company is a leading player in the ophthalmology service sector with a market capitalization of over 100 billion [1] - There is a call from investors for the company to adopt a proactive approach similar to other successful companies by increasing share buybacks and management stock purchases to boost investor confidence [1] - The company’s secretary indicated that any future plans for buybacks or management purchases will be disclosed in accordance with regulations [1]

Core Viewpoint - The company, 希玛医疗, has agreed to sell 55% of its subsidiary 阿波罗 to 明达眼镜, which will involve the cancellation of a debt of 504.9 million RMB, thereby relieving the company of all liabilities related to this debt [1] Group 1: Transaction Details - The transaction will result in 阿波罗 no longer being a non-wholly owned subsidiary of the company, and the company will not hold any equity interest in 阿波罗 post-transaction [1] - The deal price includes the cancellation and return of previously issued bonds worth 504.9 million RMB [1] Group 2: Strategic Initiatives - The company has implemented several strategic measures, focusing on ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize internal resource utilization [1]

Group 1 - The core point of the article is that Hema Medical (03309) has agreed to transfer 55% of Apollo's total issued share capital back to Mingda Glasses, which involves the cancellation of a debt of 504.9 million RMB [1] - The transaction will relieve the company of all liabilities under the aforementioned bond, indicating a strategic move to optimize internal resource utilization [1] - Following the completion of this transaction, Apollo will no longer be a non-wholly owned subsidiary of the company, and the company will not hold any equity interest in Apollo [1] Group 2 - The company is focusing on strategic initiatives, including enhancing ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize the use of internal resources [1]

Core Viewpoint - The company has agreed to transfer 55% of its stake in Apollo back to Mingda Glasses, which will also repurchase the remaining shares, resulting in Apollo no longer being a non-wholly owned subsidiary of the company [1] Group 1: Transaction Details - The agreement involves the cancellation of bonds and the return of these bonds to the company for destruction, relieving the company of its obligations under the bond [1] - Following the completion of this transaction, the company will no longer hold any equity interest in Apollo [1] Group 2: Apollo's Business Overview - Apollo is an investment holding company registered under Hong Kong law, previously owned 55% by the company and 45% by Mingda Glasses [1] - Since 2002, Apollo has been engaged in lens distribution in mainland China, employing nearly 100 staff to distribute customized lens products to public hospitals, private hospitals, and ophthalmology centers [1] Group 3: Strategic Initiatives - The group has implemented several strategic initiatives, focusing on ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize internal resource utilization [1]

Group 1 - EuroEyes Swiss, a wholly-owned subsidiary of the company, has entered into an agreement to acquire Swiss assets from Betterview Swiss for a total consideration of 12.01 million Swiss Francs (approximately 117 million HKD) [1] - The assets to be acquired include seven refractive surgery medical clinics located in Zurich, Bern, Lucerne, St. Gallen, Lugano, Lausanne, and Geneva, as well as a refractive surgery operating room in Zurich [1] - The acquisition also includes various headquarters assets such as commercial contracts, customer contracts, employment contracts, leasing contracts, and past patient agreements (excluding those retained by Betterview Swiss) [1] Group 2 - EuroEyes UK, another wholly-owned subsidiary of the company, has signed an agreement to acquire UK assets from Betterview UK for a total consideration of 200,000 Swiss Francs (approximately 184,400 GBP and 1.949 million HKD) [2] - The assets to be acquired consist of properties, assets, and rights used in Betterview UK's ophthalmic services business, which operates under the names "Betterview" or "Betterview Britain" [2] - The UK business includes services such as laser treatment and refractive surgery, but excludes certain business debts, cash on hand or in banks, and any recoverable tax amounts related to the UK business [2]